Page 26 - CBAC Newsletter 2016
P. 26
Reference List (Continued)
130. Iannotti FA, Panza E, Barrese V, Viggiano D, Soldovieri MV, Taglialatela M. Expression, localization, and
131. pharmacological role of Kv7 potassium channels in skeletal muscle proliferation, differentiation, and
survival after myotoxic insults. J Pharmacol Exp Ther. 332, 811-820, 2010.
132.
133. Kato M, Yamagata T, Kubota M, Arai H, Yamashita S, Nakagawa T, Fujii T, Sugai K, Imai K, Uster T, Chitayat D,
Weiss S, Kashii H, Kusano R, Matsumoto A, Nakamura K, Oyazato Y, Maeno M, Nishiyama K, Kodera H,
134. Nakashima M, Tsurusaki Y, Miyake N, Saito K, Hayasaka K, Matsumoto N, Saitsu H. Clinical spectrum of
early onset epileptic encephalopathies caused by KCNQ2 mutation. Epilepsia. 54, 1282-1287, 2013.
135.
136. Numis AL, Angriman M, Sullivan JE, Lewis A J, Striano P, Nabbout R, Cilio MR. KCNQ2 encephalopathy:
137. delineation of the electroclinical phenotype and treatment response. Neurology. 82, 368-370, 2014.
138.
139. Weckhuysen S, Ivanovic V, Hendrickx R, Van Coster R, Hjalgrim H, Moller RS, Gronborg S, Schoonjans AS,
140. Ceulemans B, Heavin SB, Eltze C, Horvath R, Casara G, Pisano T, Giordano L, Rostasy K, Haberlandt E,
141. Albrecht B, Bevot A, Benkel I, Syrbe S, Sheidley B, Guerrini R, Poduri A, Lemke JR, Mandelstam S,
142. Scheffer I, Angriman M, Striano P, Marini C, Suls A, De Jonghe P, Group KS. Extending the KCNQ2
143. encephalopathy spectrum: clinical and neuroimaging findings in 17 patients. Neurology, 81,
144. 1697-1703, 2013.
145.
146. Weckhuysen S, Mandelstam S, Suls A, Audenaert D, Deconinck T, Claes LR, Deprez L, Smets K, Hristova D,
Yordanova I, Jordanova A, Ceulemans B, Jansen A, Hasaerts D, Roelens F, Lagae L, Yendle S, Stanley T,
Heron SE, Mulley JC, Berkovic SF, Scheffer IE, de Jonghe P. KCNQ2 encephalopathy: emerging phenotype
of a neonatal epileptic encephalopathy. Ann. Neurol. 71, 15-25, 2012.
Shargorodsky J, Curhan GC, Farwell WR. Prevalence and characteristics of tinnitus among US adults.
Am J Med. 123, 711-718, 2010.
Sun H, Shikano S, Xiong Q, Li M. Function recovery after chemobleaching (FRAC): evidence for activity silent
membrane receptors on cell surface. Proc Natl Acad Sci. USA. 101, 16964-16969, 2004.
Xiong Q, Sun H, Li M. Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues
epileptogenic mutants. Nat Chem Biol. 3, 287-296, 2007.
Gao Z, Xiong Q, Sun H, Li M. Desensitization of chemical activation by auxiliary subunits: convergence of
molecular determinants critical for augmenting KCNQ1 potassium channels. J Biol Chem. 283,
22649-22658, 2008.
Li Y, Gamper N, Shapiro MS. Single-channel analysis of KCNQ K+ channels reveals the mechanism of
augmentation by a cysteine-modifying reagent. J Neurosci. 24, 5079-5090, 2004.
Marks R, Pearse AD, Walker AP. The effects of a shampoo containing zinc pyrithione on the control of
dandruff. Br J Dermatol. 112, 415-422, 1985.
Mathie A, Sutton GL, Clarke CE, Veale EL. Zinc and copper: pharmacological probes and endogenous
modulators of neuronal excitability. Pharmacol Ther. 111, 567-583, 2006.
Zhou P, Yu H, Gu, M, Nan FJ, Gao Z, Li M. Phosphatidylinositol 4,5-bisphosphate alters pharmacological
selectivity for epilepsy-causing KCNQ potassium channels. Proc Natl Acad Sci USA. 110,
8726-8731, 2013.
Luben V, Muller H, Lobisch M, Worz R. [Treatment of tumor pain with flupirtine. Results of a double-blind
study versus tramadol]. Fortschr Med. 112, 282-286, 1994.
Riethmuller-Winzen H. Flupirtine in the treatment of post-operative pain. Postgrad Med J.
63 Suppl 3, 61-65, 1987.
Scheef W. Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain. Postgrad Med J.
63 Suppl 3, 67-70, 1987.
Kornhuber J, Bleich S, Wiltfang J, Maler M, Parsons CG. Flupirtine shows functional NMDA receptor
antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid
communication. J Neural Transm (Vienna). 106, 857-867, 1999.
22 | CBAC Center Heartbeat